Comparing two methods for managing postmastectomy pain
Evaluation of T2, T3 Sympathectomy for Postmastectomy Pain Syndrome by Thermal Radiofrequency Versus Chemical Neurolysis Using Perfusion Index Derived Pulse Oximeter
NA · National Cancer Institute, Egypt · NCT04953507
This study is testing whether a new way to block pain after mastectomy using heat works better than a chemical method for women dealing with chronic pain.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | National Cancer Institute, Egypt (other) |
| Locations | 1 site (Cairo) |
| Trial ID | NCT04953507 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of T2, T3 sympathetic block using thermal radiofrequency compared to chemical neurolysis for treating postmastectomy pain syndrome. It focuses on measuring pain relief through the perfusion index derived from pulse oximetry. The study involves female patients aged 18 and older who experience chronic pain following mastectomy. By comparing these two interventions, the research seeks to identify the more effective pain management strategy.
Who should consider this trial
Good fit: Ideal candidates are female patients aged 18 and older with postmastectomy pain syndrome.
Not a fit: Patients with coagulation defects, severe cardiorespiratory disease, or local infections at the injection site may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for women suffering from chronic pain after mastectomy.
How similar studies have performed: Other studies have explored similar interventions for pain management, but this specific comparison of thermal radiofrequency and chemical neurolysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients with postmastectomy pain syndrome * ≥ Age 18 years * ASA II-III Exclusion Criteria: * patient refusal * coagulation defects * abnormal kidney or liver functions * local infection at site of injection * bone metastases * severe cardiorespiratory disease
Where this trial is running
Cairo
- Walaa Y Elsabeeny — Cairo, Egypt (RECRUITING)
Study contacts
- Principal investigator: Walaa Y Elsabeeny, MD — Assistant Professor of Anesthesia and Pain Management, National Cancer Institute, Cairo University
- Study coordinator: Walaa Y Elsabeeny, MD
- Email: walaa.elsabeeny@nci.cu.edu.eg
- Phone: 01007798466
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Analgesia